NCT00110708Unknown2 期
A Randomized, Placebo-Controlled Phase II Trial Evaluating Safety and Efficacy of Oral Human Immunoglobulin in the Treatment of Gastrointestinal Dysfunction Associated With Autistic Disorder in Pediatric Patients From 2 to 18 Years of Age
PediaMed Pharmaceuticals44 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2005年4月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 120
- 试验地点
- 44
- 主要终点
- Global improvement in gastrointestinal function
研究概览
简要总结
The purpose of this study is to determine if human immunoglobulin given by mouth twice a day is effective in treating the persistent gastrointestinal (GI) problems such as diarrhea, constipation, abdominal pain, and bloating, in children with autism.
详细描述
Autistic GI Dysfunction (AGID) is a term that describes a constellation of GI signs and symptoms often found in children with autistic disorder, including abdominal pain, constipation, chronic diarrhea, alternating constipation and diarrhea, gaseousness, bloating, and reflux.
The objective of this study is to assess the potential efficacy of oral immunoglobulin in reducing a wide range of GI symptoms in children and adolescents diagnosed with autistic disorder.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 2 Years 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female from 2 years to 18 years of age (up to, but not inclusive of the 18th birthday)
- •Diagnosis of autistic disorder corroborated by an Autism Diagnostic Interview - Revised (ADI-R) assessment performed by a certified investigator
- •Physician Clinical Global Impression of Severity (of Autistic Disorder)
- •History of chronic, persistent gastrointestinal disturbance
- •No elective changes in medication, diet intervention, or behavioral therapy during the study (18 weeks total)
排除标准
- •Evidence of a gastrointestinal infection or GI abnormality
- •A known diagnosis of other gastrointestinal pathology
- •Antibiotic and/or antifungal (e.g. nystatin) medication
- •Chelation therapy
- •Medication affecting gastrointestinal transit
- •Planned use of prohibited drugs or agents that could affect GI transit
- •Changes in diet intervention within 30 days prior to the screening visit
- •Changes in alternative medical therapies or dietary supplements within 30 days prior to the screening visit
- •Adding and/or changing behavior modification or psychotherapy during participation in the study
- •Adding or changing psychotropic medication during participation in the study
- •DSM-IV diagnosis of a pervasive developmental disorder other than autistic disorder
- •Evidence of a seizure disorder, diagnosis of fragile X syndrome, tuberous sclerosis complex, liver disease, pancreatic disease, cystic fibrosis, or chronic infection
- •Previous gastrointestinal surgery
- •Pregnancy
- •Participation in another investigational study
- •Significant deviation from normal laboratory test values at baseline
- •IgA deficiency (serum IgA < 5 mg/dL)
- •A history of severe hypersensitivity to human immunoglobulin
- •Treatment with any human immunoglobulin and/or immunoglobulin products
- •Any concurrent medication that would compromise subject's tolerance of drug or compliance with the protocol
结局指标
主要结局
Global improvement in gastrointestinal function
次要结局
- Assessment of behavior (improvement and severity); additional assessments of gastrointestinal conditions
研究者
研究点 (44)
Loading locations...
相似试验
已完成
3 期
A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s DiseaseAlzheimer´s DiseaseNCT00818662Baxalta now part of Shire390
已完成
2 期
Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingNCT00220779Grifols Therapeutics LLC128
已完成
不适用
Efficacy of Serum Bovine Immunoglobulin in Improving Nutritional Status in Advanced COPDAdvanced COPD (GOLD Stage 3 or 4) With CachexiaNCT02067377Medical University of South Carolina12
终止
3 期
GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic ShockSevere SepsisSeptic ShockNCT01315496Green Cross Corporation214
已完成
2 期
Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic GanglionopathyAutoimmune Autonomic Ganglionopathy (AAG)NCT01522235Beth Israel Deaconess Medical Center6